Andrei Iagaru

List of Publications by Year in Descending Order

146 papers	2,584 citations	33 h-index	45 g-index
159 ext. papers	3,202 ext. citations	5.3 avg, IF	5.41 L-index

#	Paper	IF	Citations
146	Radiotheranostics - Precision Medicine in Nuclear Medicine and Molecular Imaging.. *Nanotheranostics*, **2022**, 6, 103-117	5.6	3
145	PSMA theragnostics for metastatic castration resistant prostate cancer. *Translational Oncology*, **2022**, 22, 101438	4.9	1
144	Reduced Acquisition Time per Bed Position for PET/MRI Using Ga-RM2 or Ga-PSMA-11 in Patients With Prostate Cancer: A Retrospective Analysis. *American Journal of Roentgenology*, **2021**, 1-8	5.4	0
143	Pilot-phase PET/CT study targeting integrin in pancreatic cancer patients using the cystine-knot peptide-based F-FP-R1-MG-F2. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 1	8.8	1
142	Disparities in PET Imaging of Prostate Cancer at a Tertiary Academic Medical Center. *Journal of Nuclear Medicine*, **2021**, 62, 747-748	8.9	0
141	Ga-PSMA11 PET/CT for biochemically recurrent prostate cancer: Influence of dual-time and PMT- vs SiPM-based detectors. *Translational Oncology*, **2021**, 15, 101293	4.9	0
140	PSMA- and GRPR-Targeted PET: Results from 50 Patients with Biochemically Recurrent Prostate Cancer. *Journal of Nuclear Medicine*, **2021**, 62, 1545-1549	8.9	8
139	High-Specific-Activity-I-MIBG versus Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma. *Clinical Cancer Research*, **2021**, 27, 2989-2995	12.9	8
138	Unconventional non-amino acidic PET radiotracers for molecular imaging in gliomas. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 48, 3925-3939	8.8	7
137	Prognostic relevance of the hexosamine biosynthesis pathway activation in leiomyosarcoma. *Npj Genomic Medicine*, **2021**, 6, 30	6.2	1
136	Results of a Prospective Trial to Compare Ga-DOTA-TATE with SiPM-Based PET/CT vs. Conventional PET/CT in Patients with Neuroendocrine Tumors. *Diagnostics*, **2021**, 11,	3.8	2
135	F-FDG PET/CT for Evaluation of Post-Transplant Lymphoproliferative Disorder (PTLD). *Seminars in Nuclear Medicine*, **2021**, 51, 392-403	5.4	1
134	Will FAPI PET/CT Replace FDG PET/CT in the Next Decade? Counterpoint-No, Not So Fast!. *American Journal of Roentgenology*, **2021**, 216, 307-308	5.4	7
133	Pulmonary Adenocarcinoma Metastasis to the Breast Unexpectedly Discovered on Re-staging F-FDG PET/CT in a Woman With a Normal Screening Mammogram. *Clinical Lung Cancer*, **2021**, 22, e438-e441	4.9	1
132	An unusual presentation of recurrent T cell lymphoma: angiocentric pattern of cutaneous uptake on [F]FDG PET/CT. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 48, 1256-1257	8.8	
131	Imaging Characteristics and Diagnostic Performance of 2-deoxy-2-[F]fluoro-D-Glucose PET/CT for Melanoma Patients Who Demonstrate Hyperprogressive Disease When Treated with Immunotherapy. *Molecular Imaging and Biology*, **2021**, 23, 139-147	3.8	1
130	Positron Emission Tomography Magnetic Resonance Imaging **2021**, 15-27		

129	The Clinical Utility of F-Fluciclovine PET/CT in Biochemically Recurrent Prostate Cancer: an Academic Center Experience Post FDA Approval. *Molecular Imaging and Biology*, **2021**, 23, 614-623	3.8	3
128	High quality imaging and dosimetry for yttrium-90 (Y) liver radioembolization using a SiPM-based PET/CT scanner. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 48, 2426-2436	8.8	2
127	Diagnostic Performance of F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study. *Clinical Cancer Research*, **2021**, 27, 3674-3682	12.9	46
126	Prognostic Value of Bone Marrow Metabolism on Pretreatment F-FDG PET/CT in Patients with Metastatic Melanoma Treated with Anti-PD-1 Therapy. *Journal of Nuclear Medicine*, **2021**, 62, 1380-1383	8.9	9
125	To Scan or Not to Scan: An Unnecessary Dilemma for PSMA Radioligand Therapy. *Journal of Nuclear Medicine*, **2021**, 62, 1487-1488	8.9	5
124	Clinical Applications of PET/MR Imaging. *Radiologic Clinics of North America*, **2021**, 59, 853-874	2.3	1
123	A Clinical PET Imaging Tracer ([F]DASA-23) to Monitor Pyruvate Kinase M2-Induced Glycolytic Reprogramming in Glioblastoma. *Clinical Cancer Research*, **2021**, 27, 6467-6478	12.9	0
122	F DCFPyL PET Acquisition, Interpretation and Reporting: Suggestions Post Food and Drug Administration Approval. *Journal of Nuclear Medicine*, **2021**,	8.9	3
121	Prostate cancer: Molecular imaging and MRI. *European Journal of Radiology*, **2021**, 143, 109893	4.7	1
120	Humana and F-FDG PET/CT: Another Sequel to the Injustice of Being Judged by the Errors of Others. *Journal of Nuclear Medicine*, **2021**, 62, 1-2	8.9	
119	2021 SNMMI Highlights Lecture: General Nuclear Medicine. *Journal of Nuclear Medicine*, **2021**, 62, 12N-17N	8.9	1
118	Visualization of Diagnostic and Therapeutic Targets in Glioma With Molecular Imaging. *Frontiers in Immunology*, **2020**, 11, 592389	8.4	7
117	The Role of Positron Emission Tomography in Pancreatic Cancer and Gallbladder Cancer. *Seminars in Nuclear Medicine*, **2020**, 50, 434-446	5.4	6
116	Deep learning detection of prostate cancer recurrence with F-FACBC (fluciclovine, Axumin®) positron emission tomography. *European Journal of Nuclear Medicine and Molecular Imaging*, **2020**, 47, 2992-2997	8.8	12
115	Response to: Letter to the Editors: Re: Simultaneous PET/MRI in the Evaluation of Breast and Prostate Cancer Using Combined Na[F]F and [F]FDG: A Focus on Skeletal Lesions. *Molecular Imaging and Biology*, **2020**, 22, 221-222	3.8	1
114	The Effect of Various β Values on Image Quality and Semiquantitative Measurements in 68Ga-RM2 and 68Ga-PSMA-11 PET/MRI Images Reconstructed With a Block Sequential Regularized Expectation Maximization Algorithm. *Clinical Nuclear Medicine*, **2020**, 45, 506-513	1.7	7
113	Imaging the Distribution of Gastrin-Releasing Peptide Receptors in Cancer. *Journal of Nuclear Medicine*, **2020**, 61, 792-798	8.9	19
112	Shifting Trends and Informed Decision-Making in the Management of Graves' Disease. *Thyroid*, **2020**, 30, 351-354	6.2	2

111	Human biodistribution and radiation dosimetry of [F]DASA-23, a PET probe targeting pyruvate kinase M2. *European Journal of Nuclear Medicine and Molecular Imaging*, **2020**, 47, 2123-2130	8.8	4
110	Malignant Cutaneous Melanoma: Updates in PET Imaging. *Current Radiopharmaceuticals*, **2020**, 13, 14-23	1.8	5
109	Performance Comparison of Individual and Ensemble CNN Models for the Classification of Brain 18F-FDG-PET Scans. *Journal of Digital Imaging*, **2020**, 33, 447-455	5.3	12
108	Optimization of Zr PET Imaging for Improved Multisite Quantification and Lesion Detection Using an Anthropomorphic Phantom. *Journal of Nuclear Medicine Technology*, **2020**, 48, 54-57	1.1	2
107	Prospective Evaluation of F-DCFPyL PET/CT in Biochemically Recurrent Prostate Cancer in an Academic Center: A Focus on Disease Localization and Changes in Management. *Journal of Nuclear Medicine*, **2020**, 61, 546-551	8.9	33
106	Fungal endocarditis resembling primary cardiac malignancy in a patient with B-cell ALL with culture confirmation. *Radiology Case Reports*, **2020**, 15, 117-119	1	
105	Two Patient Studies of a Companion Diagnostic Immuno-Positron Emission Tomography (PET) Tracer for Measuring Human CA6 Expression in Cancer for Antibody Drug Conjugate (ADC) Therapy. *Molecular Imaging*, **2020**, 19, 1536012120939398	3.7	0
104	ACR Stakeholder Prostate Summit. *Journal of the American College of Radiology*, **2020**, 17, 1068-1070	3.5	1
103	Clinical application of Fluciclovine PET, choline PET and gastrin-releasing polypeptide receptor (bombesin) targeting PET in prostate cancer. *Current Opinion in Urology*, **2020**, 30, 641-648	2.8	2
102	Simultaneous PET/MRI in the Evaluation of Breast and Prostate Cancer Using Combined Na[F] F and [F]FDG: a Focus on Skeletal Lesions. *Molecular Imaging and Biology*, **2020**, 22, 397-406	3.8	10
101	Comparison of 3 Interpretation Criteria for Ga-PSMA11 PET Based on Inter- and Intrareader Agreement. *Journal of Nuclear Medicine*, **2020**, 61, 533-539	8.9	22
100	Physiological Ga-RM2 uptake in patients with biochemically recurrent prostate cancer: an atlas of semi-quantitative measurements. *European Journal of Nuclear Medicine and Molecular Imaging*, **2020**, 47, 115-122	8.8	14
99	Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy. *European Journal of Nuclear Medicine and Molecular Imaging*, **2020**, 47, 2787-2795	8.8	12
98	F-FDG PET/MR Refines Evaluation in Newly Diagnosed Metastatic Urethral Adenocarcinoma. *Nuclear Medicine and Molecular Imaging*, **2019**, 53, 296-299	1.9	1
97	Treatment and outcomes in classic Hodgkin lymphoma post-transplant lymphoproliferative disorder in children. *Pediatric Blood and Cancer*, **2019**, 66, e27803	3	2
96	The Role of PET/CT in the Imaging of Pancreatic Neoplasms. *Seminars in Ultrasound, CT and MRI*, **2019**, 40, 500-508	1.7	4
95	Serial Cardiac FDG-PET for the Diagnosis and Therapeutic Guidance of Patients With Cardiac Sarcoidosis. *Journal of Cardiac Failure*, **2019**, 25, 307-311	3.3	22
94	F-FPPRGD PET/CT in patients with metastatic renal cell cancer. *European Journal of Nuclear Medicine and Molecular Imaging*, **2019**, 46, 1518-1523	8.8	7

93	Multimodality Hyperpolarized C-13 MRS/PET/Multiparametric MR Imaging for Detection and Image-Guided Biopsy of Prostate Cancer: First Experience in a Canine Prostate Cancer Model. *Molecular Imaging and Biology*, **2019**, 21, 861-870	3.8	3
92	Prognostic value of somatostatin receptor expressing tumor volume calculated from Ga-DOTATATE PET/CT in patients with well-differentiated neuroendocrine tumors. *European Journal of Nuclear Medicine and Molecular Imaging*, **2019**, 46, 2244-2251	8.8	21
91	Evaluation of integrin ▯▯ystine knot PET tracers to detect cancer and idiopathic pulmonary fibrosis. *Nature Communications*, **2019**, 10, 4673	17.4	39
90	Ga Scatter Correction to Eliminate Halo-Artifacts in PET Imaging. *Urology*, **2019**, 131, 262	1.6	
89	Improved Scatter Correction to Eliminate Halo Artifacts for Ga-Labeled Radiopharmaceuticals in PET Imaging. *Journal of Nuclear Medicine*, **2019**, 60, 1334	8.9	
88	Initial experience with a PET/computed tomography system using silicon photomultiplier detectors. *Nuclear Medicine Communications*, **2019**, 40, 1174-1178	1.6	1
87	Imaging gastrin-releasing peptide receptors (GRPRs) in prostate cancer. *Clinical and Translational Imaging*, **2019**, 7, 39-44	2	3
86	Total-Body PET/MRI in Oncological Applications **2018**, 169-184		
85	PET/MRI in Brain Tumors **2018**, 185-222		
84	PET/MRI in Prostate Cancer **2018**, 341-371		
83	Prostate Cancer Theranostics Targeting Gastrin-Releasing Peptide Receptors. *Molecular Imaging and Biology*, **2018**, 20, 501-509	3.8	43
82	Initial experience with a SiPM-based PET/CT scanner: influence of acquisition time on image quality. *EJNMMI Physics*, **2018**, 5, 9	4.4	33
81	Prospective Evaluation of Ga-RM2 PET/MRI in Patients with Biochemical Recurrence of Prostate Cancer and Negative Findings on Conventional Imaging. *Journal of Nuclear Medicine*, **2018**, 59, 803-808	8.9	46
80	Standard OSEM vs. regularized PET image reconstruction: qualitative and quantitative comparison using phantom data and various clinical radiopharmaceuticals. *American Journal of Nuclear Medicine and Molecular Imaging*, **2018**, 8, 110-118	2.2	18
79	Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program. *Oncologist*, **2018**, 23, 193-202	5.7	51
78	Combined 68Ga-NOTA-PRGD2 and 18F-FDG PET/CT Can Discriminate Uncommon Meningioma Mimicking High-Grade Glioma. *Clinical Nuclear Medicine*, **2018**, 43, 648-654	1.7	11
77	F-florbetaben whole-body PET/MRI for evaluation of systemic amyloid deposition. *EJNMMI Research*, **2018**, 8, 66	3.6	21
76	Gallium 68 PSMA-11 PET/MR Imaging in Patients with Intermediate- or High-Risk Prostate Cancer. *Radiology*, **2018**, 288, 495-505	20.5	68

75	Nuclear Medicine Imaging Techniques for Detection of Skeletal Metastases in Breast Cancer. *PET Clinics*, **2018**, 13, 383-393	2.2	10
74	Imaging of Prostate Cancer Using Gallium-68-Labeled Bombesin. *PET Clinics*, **2017**, 12, 159-171	2.2	8
73	Dual-Integrin and Gastrin-Releasing Peptide Receptor-Targeting PET Radiotracer (Ga-BBN-RGD). *Journal of Nuclear Medicine*, **2017**, 58, 1706	8.9	1
72	Initial Experience With Simultaneous 18F-FDG PET/MRI in the Evaluation of Cardiac Sarcoidosis and Myocarditis. *Clinical Nuclear Medicine*, **2017**, 42, e328-e334	1.7	38
71	Assessment of skeletal tumour burden on 18F-NaF PET/CT using a new quantitative method. *Nuclear Medicine Communications*, **2017**, 38, 325-332	1.6	15
70	Will GRPR Compete with PSMA as a Target in Prostate Cancer?. *Journal of Nuclear Medicine*, **2017**, 58, 1883-1884	8.9	16
69	18F-FDG silicon photomultiplier PET/CT: A pilot study comparing semi-quantitative measurements with standard PET/CT. *PLoS ONE*, **2017**, 12, e0178936	3.7	34
68	Semiquantitative Assessment of F-FDG Uptake in the Normal Skeleton: Comparison Between PET/CT and Time-of-Flight Simultaneous PET/MRI. *American Journal of Roentgenology*, **2017**, 209, 1136-1142	5.4	4
67	An 8-week open label trial of l -Threonic Acid Magnesium Salt in patients with mild to moderate dementia. *Personalized Medicine in Psychiatry*, **2017**, 4-6, 7-12	1.1	2
66	Conspicuity of Malignant Lesions on PET/CT and Simultaneous Time-Of-Flight PET/MRI. *PLoS ONE*, **2017**, 12, e0167262	3.7	2
65	Pilot Comparison of Ga-RM2 PET and Ga-PSMA-11 PET in Patients with Biochemically Recurrent Prostate Cancer. *Journal of Nuclear Medicine*, **2016**, 57, 557-62	8.9	122
64	PET Imaging Toward Individualized Management of Urologic and Gynecologic Malignancies. *PET Clinics*, **2016**, 11, 261-72	2.2	1
63	Improvements in PET Image Quality in Time of Flight (TOF) Simultaneous PET/MRI. *Molecular Imaging and Biology*, **2016**, 18, 776-81	3.8	24
62	Pilot prospective evaluation of (18)F-FPPRGD2 PET/CT in patients with cervical and ovarian cancer. *European Journal of Nuclear Medicine and Molecular Imaging*, **2016**, 43, 1047-55	8.8	17
61	Clinical significance of extraskeletal computed tomography findings on 18F-NaF PET/CT performed for osseous metastatic disease evaluation. *Nuclear Medicine Communications*, **2016**, 37, 975-82	1.6	2
60	Spectrum of 68Ga-DOTA TATE Uptake in Patients With Neuroendocrine Tumors. *Clinical Nuclear Medicine*, **2016**, 41, e281-7	1.7	24
59	A Prospective, Matched Comparison Study of SUV Measurements From Time-of-Flight Versus Non-Time-of-Flight PET/CT Scanners. *Clinical Nuclear Medicine*, **2016**, 41, e323-6	1.7	7
58	Dual-tracer imaging of malignant bone involvement using PET. *Clinical and Translational Imaging*, **2015**, 3, 123-131	2	1

57	Semiquantitative Analysis of the Biodistribution of the Combined □F-NaF and □F-FDG Administration for PET/CT Imaging. *Journal of Nuclear Medicine*, **2015**, 56, 688-94	8.9	14
56	Simultaneous whole-body time-of-flight 18F-FDG PET/MRI: a pilot study comparing SUVmax with PET/CT and assessment of MR image quality. *Clinical Nuclear Medicine*, **2015**, 40, 1-8	1.7	59
55	Detection of osseous metastasis by 18F-NaF/18F-FDG PET/CT versus CT alone. *Clinical Nuclear Medicine*, **2015**, 40, e173-7	1.7	19
54	Stereotactic ablative radiotherapy for the treatment of refractory cardiac ventricular arrhythmia. *Circulation: Arrhythmia and Electrophysiology*, **2015**, 8, 748-50	6.4	103
53	Biodistribution of the □F-FPPRGD□PET radiopharmaceutical in cancer patients: an atlas of SUV measurements. *European Journal of Nuclear Medicine and Molecular Imaging*, **2015**, 42, 1850-8	8.8	34
52	Whole-body simultaneous time-of-flight PET-MRI: early experience with clinical studies. *EJNMMI Physics*, **2015**, 2, A64	4.4	
51	Imaging patients with breast and prostate cancers using combined 18F NaF/18F FDG and TOF simultaneous PET/ MRI. *EJNMMI Physics*, **2015**, 2, A65	4.4	2
50	Glioblastoma Multiforme Recurrence: An Exploratory Study of (18)F FPPRGD2 PET/CT. *Radiology*, **2015**, 277, 497-506	20.5	39
49	Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer. *Journal of Nuclear Medicine*, **2015**, 56, 1862-8	8.9	78
48	18F-Fluoride PET in the Assessment of Malignant Bone Disease. *Journal of Nuclear Medicine*, **2015**, 56, 1476-7	8.9	3
47	18F-sodium fluoride PET/CT in oncology: an atlas of SUVs. *Clinical Nuclear Medicine*, **2015**, 40, e228-31	1.7	32
46	Combined 18F-NaF and 18F-FDG PET/CT in the Evaluation of Sarcoma Patients. *Clinical Nuclear Medicine*, **2015**, 40, 720-4	1.7	14
45	Scanner dependent noise properties of the Q. Clear PET image reconstruction tool **2015**,		1
44	(18)F-FPPRGD2 PET/CT: pilot phase evaluation of breast cancer patients. *Radiology*, **2014**, 273, 549-59	20.5	41
43	(18)F-FDG PET/CT in the management of patients with post-transplant lymphoproliferative disorder. *Nuclear Medicine Communications*, **2014**, 35, 276-81	1.6	33
42	Imaging tumor angiogenesis: the road to clinical utility. *American Journal of Roentgenology*, **2013**, 201, W183-91	5.4	48
41	Combined 18F-fluoride and 18F-FDG PET/CT: a response based on actual data from prospective studies. *European Journal of Nuclear Medicine and Molecular Imaging*, **2013**, 40, 1922-4	8.8	3
40	Pilot prospective evaluation of 99mTc-MDP scintigraphy, 18F NaF PET/CT, 18F FDG PET/CT and whole-body MRI for detection of skeletal metastases. *Clinical Nuclear Medicine*, **2013**, 38, e290-6	1.7	51

39	Combined 18F-fluoride and 18F-FDG PET/CT scanning for evaluation of malignancy: results of an international multicenter trial. *Journal of Nuclear Medicine*, **2013**, 54, 176-83	8.9	47
38	Prospective comparison of combined 18F-FDG and 18F-NaF PET/CT vs. 18F-FDG PET/CT imaging for detection of malignancy. *European Journal of Nuclear Medicine and Molecular Imaging*, **2012**, 39, 262-70	8.8	50
37	(18)F NaF PET/CT in the Assessment of Malignant Bone Disease. *PET Clinics*, **2012**, 7, 263-74	2.2	5
36	Prospective evaluation of (99m)Tc MDP scintigraphy, (18)F NaF PET/CT, and (18)F FDG PET/CT for detection of skeletal metastases. *Molecular Imaging and Biology*, **2012**, 14, 252-9	3.8	118
35	Demonstration of peripheral nerve root involvement by non-Hodgkin's lymphoma on 18F-FDG PET/CT. *European Journal of Nuclear Medicine and Molecular Imaging*, **2012**, 39, 729-30	8.8	4
34	Thyroid stunning: fact or fiction?. *Seminars in Nuclear Medicine*, **2011**, 41, 105-12	5.4	54
33	FDG-PET/CT in cancers of the head and neck: what is the definition of whole body scanning?. *Molecular Imaging and Biology*, **2011**, 13, 362-7	3.8	6
32	Reply: Combined 18F-FDG and Fluoride Approach in PET/CT Imaging: Is There a Clinical Future? **2010**, 51, 166-167		3
31	(18)F-FDG-PET and PET/CT for Evaluating Primary Bone Tumors. *PET Clinics*, **2010**, 5, 327-39	2.2	1
30	Current concepts and future directions in radioimmunotherapy. *Current Drug Discovery Technologies*, **2010**, 7, 253-62	1.5	10
29	131I-Tositumomab (Bexxar) vs. 90Y-Ibritumomab (Zevalin) therapy of low-grade refractory/relapsed non-Hodgkin lymphoma. *Molecular Imaging and Biology*, **2010**, 12, 198-203	3.8	25
28	Novel strategy for a cocktail 18F-fluoride and 18F-FDG PET/CT scan for evaluation of malignancy: results of the pilot-phase study. *Journal of Nuclear Medicine*, **2009**, 50, 501-5	8.9	94
27	Efficacy of 18F-FDG PET/CT in the evaluation of patients with recurrent cervical carcinoma. *European Journal of Nuclear Medicine and Molecular Imaging*, **2009**, 36, 1952-9	8.8	67
26	Evaluation by 18F-FDG-PET of patients with anal squamous cell carcinoma. *Hellenic Journal of Nuclear Medicine*, **2009**, 12, 26-9	0.6	14
25	Perspectives of molecular imaging and radioimmunotherapy in lymphoma. *Radiologic Clinics of North America*, **2008**, 46, 243-52, viii	2.3	6
24	90Y-ibritumomab therapy in refractory non-Hodgkin's lymphoma: observations from 111In-ibritumomab pretreatment imaging. *Journal of Nuclear Medicine*, **2008**, 49, 1809-12	8.9	33
23	18F-FDG PET/CT evaluation of patients with ovarian carcinoma. *Nuclear Medicine Communications*, **2008**, 29, 1046-51	1.6	49
22	F-18 FDG PET and PET/CT evaluation of response to chemotherapy in bone and soft tissue sarcomas. *Clinical Nuclear Medicine*, **2008**, 33, 8-13	1.7	35

21	123I MIBG mapping with intraoperative gamma probe for recurrent neuroblastoma. *Molecular Imaging and Biology*, **2008**, 10, 19-23	3.8	5
20	Rhabdomyosarcoma diffusely metastatic to the bone marrow: suspicious findings on 99mTc-MDP bone scintigraphy confirmed by (18)F-18 FDG PET/CT and bone marrow biopsy. *European Journal of Nuclear Medicine and Molecular Imaging*, **2008**, 35, 1746	8.8	11
19	(18)F-FDG-PET/CT evaluation of response to treatment in lymphoma: when is the optimal time for the first re-evaluation scan?. *Hellenic Journal of Nuclear Medicine*, **2008**, 11, 153-6	0.6	7
18	PET Imaging of Skull Base Neoplasms. *PET Clinics*, **2007**, 2, 489-510	2.2	2
17	Advances in metabolic imaging for surgical oncology. *Surgical Oncology Clinics of North America*, **2007**, 16, 273-92	2.7	1
16	Breast MRI and 18F FDG PET/CT in the management of breast cancer. *Annals of Nuclear Medicine*, **2007**, 21, 33-8	2.5	26
15	Detection of occult medullary thyroid cancer recurrence with 2-deoxy-2-[F-18]fluoro-D-glucose-PET and PET/CT. *Molecular Imaging and Biology*, **2007**, 9, 72-7	3.8	33
14	Molecular imaging can accelerate anti-angiogenic drug development and testing. *Nature Clinical Practice Oncology*, **2007**, 4, 556-7		23
13	F-18 FDG PET/CT demonstration of an adrenal metastasis in a patient with anaplastic thyroid cancer. *Clinical Nuclear Medicine*, **2007**, 32, 13-5	1.7	11
12	F-18 FDG PET visualization of urinary leak after nephrostomy tube removal. *Clinical Nuclear Medicine*, **2007**, 32, 168-9	1.7	2
11	F-18 FDG PET/CT in the management of thyroid cancer. *Clinical Nuclear Medicine*, **2007**, 32, 690-5	1.7	49
10	Treatment of thyrotoxicosis. *Journal of Nuclear Medicine*, **2007**, 48, 379-89	8.9	30
9	Demonstration of a right inguinal hernia containing urinary bladder diverticulum on whole-body bone scan and pelvic CT. *European Journal of Nuclear Medicine and Molecular Imaging*, **2006**, 33, 234	8.8	3
8	PET/CT follow-up in nonossifying fibroma. *American Journal of Roentgenology*, **2006**, 187, 830-2	5.4	5
7	F-18 FDG PET evaluation of bronchial plasmacytoma with CT and MRI correlation. *Clinical Nuclear Medicine*, **2006**, 31, 279-80	1.7	6
6	F-18 FDG PET/CT evaluation of osseous and soft tissue sarcomas. *Clinical Nuclear Medicine*, **2006**, 31, 754-60	1.7	42
5	18F-FDG PET and PET/CT for detection of pulmonary metastases from musculoskeletal sarcomas. *Nuclear Medicine Communications*, **2006**, 27, 795-802	1.6	68
4	F-18 FDG PET imaging of urinary bladder oat cell carcinoma with widespread osseous metastases. *Clinical Nuclear Medicine*, **2006**, 31, 476-8	1.7	5

3	Demonstration of an ectopic mediastinal parathyroid adenoma on Tc-99m sestamibi myocardial perfusion scintigraphy. *Journal of Nuclear Cardiology*, **2006**, 13, 719-21	2.1	5
2	2-Deoxy-2-[18F]fluoro-D-glucose-positron emission tomography and positron emission tomography/computed tomography diagnosis of patients with recurrent papillary thyroid cancer. *Molecular Imaging and Biology*, **2006**, 8, 309-14	3.8	17
1	Failed atrial septal defect repair versus pulmonary hypertension with right ventricular failure. *Clinical Nuclear Medicine*, **2005**, 30, 767-8	1.7	